News
Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now ...
Good news, right? Well, kinda. Under CEO David Joyner, a 30-year company veteran who took over in October, the company has ...
The insurance business is shaky but care delivery subsidiaries such as Optum, Evernorth Health Services, CenterWell and ...
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
Novo Nordisk stock jumped more than 2% in trading Wednesday after beating Wall Street's profit estimates for the first ...
Sales are booming for Lilly's tirzepatide products, Mounjaro and Zepbound. The company's market share for incretin analogs ...
We expect disappointing results in the first quarter will be balanced by higher-than-anticipated growth in the second half.
Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...
The maker of Ozempic and Wegovy expects lower sales and profit growth this year despite recent victories against compounders.
Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...
Novo Nordisk is collaborating with multiple telehealth organizations in an effort to increase patient access to authentic Wegovy.
Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results